BioCentury | Sep 20, 2019
Product Development

European patent proposal presents paradoxical risk for academics and biotechs

...the investment.” According to Helmut Buschmann, head of chemistry, pharmaceutical development and patent affairs at AiCuris...
BioCentury | Jul 9, 2019
Company News

In Lysando’s Artilysin tech, AiCuris sees means to evade antibiotic resistance

...platform to develop an array of phage-derived antibacterial proteins spanning broad and narrow spectrum activity. AiCuris...
...to treat human Gram-negative and Gram-positive infections, including those associated with pneumonia and cystic fibrosis. AiCuris...
...development within two years. He said Lysando will generate Artilysin candidates for laboratory evaluation, while AiCuris...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Aug 10, 2018
Finance

Super-sized ambitions

...companies Adaptimmune Therapeutics plc and Immunocore Ltd. -- all had the backing of U.S. investors. AiCuris...
...cap sits at $1.5 billion. Companies and Institutions Mentioned Adaptimmune Therapeutics plc (NASDAQ:ADAP), Abingdon, U.K. AiCuris...
BioCentury | Apr 20, 2018
Company News

AiCuris, Max Planck partner to develop anti-infectives

...of Molecular Physiology (Dortmund, Germany) to develop new compounds to treat viral and bacterial infections. AiCuris...
...Planck Institute of Molecular Physiology, Dortmund, Germany AiCuris Anti-infective Cures GmbH, Wuppertal, Germany Business: Infectious Mary Romeo AiCuris...
BioCentury | Jan 9, 2018
Finance

Stars in China

...pressure in adults with septic or other distributive shock Merck & Co. Inc. (NYSE:MRK) / AiCuris...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 16, 2017
Clinical News

CHMP recommends Merck's Prevymis for CMV

...the quinazoline-based inhibitor of the CMV terminase protein from AiCuris Anti-infective Cures GmbH (Wuppertal, Germany). AiCuris...
...Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Prevymis letermovir (MK-8228; AIC246) Business: Infectious Elizabeth S. Eaton AIC246 letermovir MK-8228 Prevymis AiCuris...
BioCentury | Nov 10, 2017
Company News

CHMP recommends basket of therapies

...Merck has exclusive, worldwide rights to the quinazoline-based inhibitor of the CMV terminase protein from AiCuris...
...GmbH (Wuppertal, Germany). FDA approved Prevymis on Thursday (see BioCentury Extra, Nov. 9) . Elizabeth S. Eaton Adynovi benralizumab Prevymis AiCuris...
BioCentury | Nov 10, 2017
Clinical News

FDA approves Merck's Premyvis letermovir for CMV

...and $270 for injection. The approval triggered a €105 million ($121.6 million) milestone payment to AiCuris...
...NYSE:MRK), Kenilworth, N.J. AiCuris Anti-infective Cures GmbH, Wuppertal, Germany Product: Prevymis letermovir (MK-8228) Business: Infectious Allison Johnson AIC246 letermovir MK-8228 AiCuris...
Items per page:
1 - 10 of 49
BioCentury | Sep 20, 2019
Product Development

European patent proposal presents paradoxical risk for academics and biotechs

...the investment.” According to Helmut Buschmann, head of chemistry, pharmaceutical development and patent affairs at AiCuris...
BioCentury | Jul 9, 2019
Company News

In Lysando’s Artilysin tech, AiCuris sees means to evade antibiotic resistance

...platform to develop an array of phage-derived antibacterial proteins spanning broad and narrow spectrum activity. AiCuris...
...to treat human Gram-negative and Gram-positive infections, including those associated with pneumonia and cystic fibrosis. AiCuris...
...development within two years. He said Lysando will generate Artilysin candidates for laboratory evaluation, while AiCuris...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Aug 10, 2018
Finance

Super-sized ambitions

...companies Adaptimmune Therapeutics plc and Immunocore Ltd. -- all had the backing of U.S. investors. AiCuris...
...cap sits at $1.5 billion. Companies and Institutions Mentioned Adaptimmune Therapeutics plc (NASDAQ:ADAP), Abingdon, U.K. AiCuris...
BioCentury | Apr 20, 2018
Company News

AiCuris, Max Planck partner to develop anti-infectives

...of Molecular Physiology (Dortmund, Germany) to develop new compounds to treat viral and bacterial infections. AiCuris...
...Planck Institute of Molecular Physiology, Dortmund, Germany AiCuris Anti-infective Cures GmbH, Wuppertal, Germany Business: Infectious Mary Romeo AiCuris...
BioCentury | Jan 9, 2018
Finance

Stars in China

...pressure in adults with septic or other distributive shock Merck & Co. Inc. (NYSE:MRK) / AiCuris...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 16, 2017
Clinical News

CHMP recommends Merck's Prevymis for CMV

...the quinazoline-based inhibitor of the CMV terminase protein from AiCuris Anti-infective Cures GmbH (Wuppertal, Germany). AiCuris...
...Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Prevymis letermovir (MK-8228; AIC246) Business: Infectious Elizabeth S. Eaton AIC246 letermovir MK-8228 Prevymis AiCuris...
BioCentury | Nov 10, 2017
Company News

CHMP recommends basket of therapies

...Merck has exclusive, worldwide rights to the quinazoline-based inhibitor of the CMV terminase protein from AiCuris...
...GmbH (Wuppertal, Germany). FDA approved Prevymis on Thursday (see BioCentury Extra, Nov. 9) . Elizabeth S. Eaton Adynovi benralizumab Prevymis AiCuris...
BioCentury | Nov 10, 2017
Clinical News

FDA approves Merck's Premyvis letermovir for CMV

...and $270 for injection. The approval triggered a €105 million ($121.6 million) milestone payment to AiCuris...
...NYSE:MRK), Kenilworth, N.J. AiCuris Anti-infective Cures GmbH, Wuppertal, Germany Product: Prevymis letermovir (MK-8228) Business: Infectious Allison Johnson AIC246 letermovir MK-8228 AiCuris...
Items per page:
1 - 10 of 49